Japan's Shionogi Says Its Covid Pill's Sales May Hit $2 Billion

The transcript discusses the development and market potential of COVID pills by various companies, including Shinogi. It covers the clinical trials in Japan, data collection, and analysis. The potential sales and market challenges are addressed, highlighting the unpredictability of virus infections. The need for partnerships to expand globally is also discussed, with mentions of potential partners like GSK and Sanofi.

What is the price of the Merck treatment mentioned in the discussion?

How many companies is the speaker currently in talks with for partnership?